Towards a New Understanding of the Molecular Mechanisms of Cardiovascular Disease
Fatty acid micelles and vesicles with an acidic core can develop, and the physiological manifestations of such process in the human body. The process allows the understanding of arterial calcification, why coronary arteries, aorta, and carotids are the most affected vessels, and the preferential distribution of plaques on the areas of the endothelium where shear stress is lower. The role of systemic buffers in the control of blood pH, and the effects of pollutants, namely heavy metals, diet, and ethanol intake, on cardiovascular risks. The most important cardiovascular risk factors are explained based on their effect on either lowering blood pH or increasing blood FFA concentration, or both. Cardiovascular risk protection factors also find an explanation within the proposed framework. As a final point, the importance of knowing blood pH and concentrations of free fatty acids and albumin concentrations in the blood is emphasized in developing a strategy of prevention of cardiovascular disease.
Scientist Home Vascular Study
Triglyceride (1,2,15), Cholesterol (6,15), Blood pressure (5,7,8), Smooth blood flow (3,4,11), Cardiovascular and cerebrovascular health (9,10,14,15), Arterial elasticity (12,13,15)
To be taken every morning and night after meal. Dissolve 1 teaspoon of powder in 250 ml of warm water.
Try for 2 months. If there is no positive progress, suggest to stop taking and seek medical advice promptly.
If positive progress is observed, you may continue and monitor the progress between 3 and 12 months.
Upon attaining satisfactory results, may take half of the recommended dosage regularly for maintenance purposes.
Data from cholesterol and blood pressure tests are good references on progress.
Suggest to check blood pressure level regularly and cholesterol levels on a monthly basis.
Eat less fried or roasted food, maintain a light diet.
Involve an adequate amount of aerobic exercise step by step to strengthen cardiopulmonary function.
Drink more water (2000 ml per day) to facilitate metabolism.
Kianbakht, S., Abasi, B., Perham, M. and HashemDabaghian, F. (2011). Antihyperlipidemic Effects of Salvia officinalis L. Leaf Extract in Patients with Hyperlipidemia: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Phytotherapy Research, 25(12), pp.1849-1853.
Sá, C., Ramos, A., Azevedo, M., Lima, C., Fernandes-Ferreira, M. and Pereira-Wilson, C. (2009). Sage Tea Drinking Improves Lipid Profile and Antioxidant Defences in Humans. International Journal of Molecular Sciences, 10(9), pp.3937-3950.
Sumi, H., Hamada, H., Nakanishi, K. and Hiratani, H. (1990). Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. ActaHaematol, 84, pp.139-143.
Suzuki, Y., Kondo, K., Ichise, H., Tsukamoto, Y., Urano, T. and Umemura, K. (2003). Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition, 19(3), pp.261-264.
KIM, J., GUM, S., PAIK, J., LIM, H., KIM, K., OGASAWARA, K., INOUE, K., PARK, S., JANG, Y. and LEE, J. (2008). Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. Hypertension Research, 31(8), pp.1583-1588.
Gurrola-Díaz, C., García-López, P., Sánchez-Enríquez, S., Troyo-Sanromán, R., Andrade-González, I. and Gómez-Leyva, J. (2010). Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy). Phytomedicine, 17(7), pp.500-505.
Herrera-Arellano, A., Miranda-Sánchez, J., Ávila-Castro, P., Herrera-Álvarez, S., Jiménez-Ferrer, J., Zamilpa, A., Román-Ramos, R., Ponce-Monter, H. and Tortoriello, J. (2006). Clinical Effects Produced by a Standardized Herbal Medicinal Product of Hibiscus sabdariffa on Patients with Hypertension. A Randomized, Double-blind, Lisinopril-Controlled Clinical Trial. PlantaMedica, 73(01), pp.6-12.
HajiFaraji, M. and HajiTarkhani, A. (1999). The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. Journal of Ethnopharmacology, 65(3), pp.231-236.
Yamori, Y., Taguchi, T., Hamada, A., Kunimasa, K., Mori, H. and Mori, M. (2010). Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. Journal of Biomedical Science, 17(Suppl 1), p.S6.
Wójcik, O., Koenig, K., Zeleniuch-Jacquotte, A., Costa, M. and Chen, Y. (2010). The potential protective effects of taurine on coronary heart disease. Atherosclerosis, 208(1), pp.19-25.
Liu, M., Wallmon, A., Olsson-Mortlock, C., Wallin, R. and Saldeen, T. (2003). Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J ClinNutr, 77, pp.700-6.
Littarru, G. and Tiano, L. (2007). Bioenergetic and Antioxidant Properties of Coenzyme Q10: Recent Developments. Molecular Biotechnology, 37(1), pp.31-37.
Kumar, A., Kaur, H., Devi, P. and Mohan, V. (2009). Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacology & Therapeutics, 124(3), pp.259-268.
Pepe, S., Marasco, S., Haas, S., Sheeran, F., Krum, H. and Rosenfeldt, F. (2007). Coenzyme Q10 in cardiovascular disease. Mitochondrion, 7, pp.S154-S167.
He, S., Qian, Z., Wen, N., Tang, F., Xu, G. and Zhou, C. (2007). Influence of Crocetin on experimental atherosclerosis in hyperlipidamic-diet quails. European Journal of Pharmacology, 554(2-3), pp.191-195.
This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.